- Ventripoint Diagnostics (VPT) will be hosting an exhibit at the 2022 British Society of Echocardiography Conference in London, England
- This conference will further connect Ventripoint to the global echo community and demonstrate how the VMS+ is a reliable and effective cardiac diagnostic tool
- This will also provide valuable networking opportunities for Ventripoint’s global partners
- VentriPoint is a Canada-based medical device company
- VentriPoint Diagnostics Ltd. (VPT) is down 1.85 per cent, trading at C$0.265 per share at 3:09 pm ET
Ventripoint Diagnostics (VPT) will be hosting an exhibit at the 2022 British Society of Echocardiography Conference in London, England.
The conference will take place from October 14-15, 2022. Dr. Gregory Skinner, one of Ventripoint’s clinical advisors will be giving a presentation on his experience using the VMS system. This will provide excellent exposure for the VMS system and its capabilities for cardiologists and clinicians.
This conference will further connect Ventripoint to the global echo community and demonstrate how the VMS+ is a reliable and effective cardiac diagnostic tool. Ventripoint’s local UK distributor, Cardiologic, will also be participating in the event. This will also provide valuable networking opportunities for Ventripoint’s global partners.
The British Society of Echocardiography (BSE) is a registered charity supporting clinical echocardiography professionals to provide the highest standard of care in echocardiography. The conference will be attended both in person and virtually, offering a unique hybrid experience.
VentriPoint is a Canada-based medical device company. It is primarily engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease.
VentriPoint Diagnostics Ltd. (VPT) is down 1.85 per cent, trading at C$0.265 per share at 3:05 pm ET.